失败经导管主动脉瓣生物瓣的再次干预:全州范围经验
基于密歇根州STS数据库与TVT注册研究2012–2019年9694例TAVR患者,再次干预87例(0.90%),其中外科瓣膜取出34例、再次TAVR 53例。自膨胀瓣膜再次干预率高于球囊扩张瓣膜(0.58% vs 0.19%,P=.001),外科取出组30天死亡率15%高于再次TAVR 2%(P=.032)。
要点
- TAVR后再干预率低(0.90%)但逐年增加,2019年外科取出占再干预65%。
- 自膨胀瓣膜外科取出率高于球囊扩张瓣膜(0.58% vs 0.19%,P=.001)。
- 外科瓣膜取出30天死亡率15%,再次TAVR为2%(P=.032)。
核心结论
- 主动脉瓣再干预仍罕见但呈增加趋势,外科装置取出的临床影响显著。
- 自膨胀装置患者中经导管主动脉瓣取出的比例显著更高。
研究设计与样本
- 回顾性队列研究,利用密歇根州STS数据库与TVT注册,纳入2012–2019年9694例TAVR患者。
- 再干预定义为外科TAV取出或再次TAVR,共87例(0.90%)。
主要发现
- 再干预87例中外科TAV取出34例、再次TAVR 53例。
- 再干预例数从2012–2013年0例增至2019年26例,2019年外科取出占再干预65%。
- 自膨胀装置再干预率高于球囊扩张装置(0.58% [23/3957] vs 0.19% [11/5737];P=.001),再次TAVR率相似(0.61% [24/3957] vs 0.51% [29/5737];P=.51)。
- 外科TAV取出组STS预测死亡风险更高;30天死亡率外科取出15% vs 再次TAVR 2%(P=.032),O/E比1.8 vs 0.3(P=.018)。
- 外科取出患者中再次TAVR禁忌原因包括解剖不适合(75%)、需其他心脏手术(29%)、装置相关其他结构问题(18%)、心内膜炎(12%)。
关键数值与推荐
- 再干预率0.90%(87/9694)。
- 自膨胀装置外科取出率0.58%(23/3957)vs 球囊扩张0.19%(11/5737),P=.001。
- 再次TAVR率0.61%(24/3957)vs 0.51%(29/5737),P=.51。
- 外科取出30天死亡率15%,再次TAVR 2%,P=.032;O/E比1.8 vs 0.3,P=.018。
临床怎么用
- TAVR后需监测生物瓣失败,再干预选择应评估解剖适宜性及合并手术需求。
- 自膨胀瓣膜患者外科取出风险较高,再次TAVR前需仔细评估禁忌原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the rapid adoption of transcatheter aortic valve replacement since its approval, the frequency and outcomes of aortic valve reintervention after transcatheter aortic valve replacement are poorly understood. METHODS: Valve reinterventions, either surgical transcatheter aortic valve explantation or repeat transcatheter aortic valve replacement, between 2012 and 2019 were queried using the Society of Thoracic Surgeons Database and the Transcatheter Valve Therapy Registry through the Michigan Statewide quality collaborative. The reintervention frequency and clinical outcomes including observed-to-expected mortality ratio using Society of Thoracic Surgeons Predicted Risk of Mortality were reviewed. RESULTS: Among 9694 transcatheter aortic valve replacement recipients, a total of 87 patients (0.90%) received a reintervention, consisting of 34 transcatheter aortic valve explants and 53 repeat transcatheter aortic valve replacement procedures. The transcatheter aortic valve explant group demonstrated a higher Society of Thoracic Surgeons Predicted Risk of Mortality. Reintervention cases increased from 0 in 2012 and 2013 to 26 in 2019. The proportion of transcatheter aortic valve explants among all reinterventions increased and was 65% in 2019. Self-expandable devices had a higher reintervention rate than balloon-expandable devices secondary to a higher transcatheter aortic valve explant frequency (0.58% [23/3957] vs 0.19% [11/5737]; P = .001), whereas repeat transcatheter aortic valve replacement rates were similar (0.61% [24/3957] vs 0.51% [29/5737]; P = .51). Among patients with transcatheter aortic valve explants, contraindications to repeat transcatheter aortic valve replacement included unfavorable anatomy (75%), need for other cardiac surgery (29%), other structural issues by transcatheter aortic valve device (18%), and endocarditis (12%). For transcatheter aortic valve explant and repeat transcatheter aortic valve replacement, the 30-day mortality was 15% and 2% (P = .032) and the observed-to-expected mortality ratio was 1.8 and 0.3 (P = .018), respectively. CONCLUSIONS: Aortic valve reintervention remains rare but is increasing. The clinical impact of surgical device explantation was substantial, and the proportion of transcatheter aortic valve explants was significantly higher in patients with a self-expandable device.
引用
- Fukuhara S, Tanaka D, Brescia AA, et al. Aortic valve reintervention in patients with failing transcatheter aortic bioprostheses: A statewide experience. J Thorac Cardiovasc Surg. 2021. PMID: 34538638. doi:10.1016/j.jtcvs.2021.08.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。